Therapeutic and prophylactic gastrectomy in a family with hereditary diffuse gastric cancer secondary to a CDH1 mutation: a case series by Gjyshi, Olsi et al.
CASE REPORT Open Access
Therapeutic and prophylactic gastrectomy
in a family with hereditary diffuse gastric
cancer secondary to a CDH1 mutation: a
case series
Olsi Gjyshi1, Pankaj Vashi2, Laura Seewald3, Mitra Kohan4, Elham Abboud2, Eric Fowler2, Revathi Suppiah2
and Hatem Halabi2*
Abstract
Background: Gastric cancer is the fifth most prevalent and the third most lethal cancer worldwide, causing
approximately 720,000 deaths annually. Although most cases of gastric cancers are sporadic, one of its inherited forms,
hereditary diffuse gastric cancer (HDGC), constitutes about 1–3% of cases. Interestingly, females in families with HDGC
are also predisposed to developing lobular breast cancer (LBC). Recent analyses have identified loss-of-function
germline mutations in cadherein-1 (CDH1) as a culprit in HDGC and LBC. This discovery fueled several sequencing
analyses and case series reports analyzing the pattern of inheritance of CDH1 and its propensity to induce HDGC. In
2015, a multinational and multidisciplinary task force updated the guidelines and criteria for screening, diagnosing, and
managing HDGC.
Case presentation: Here, we present a case series of three siblings with family history of HDGC who tested positive
for the CDH1 mutation and describe their surgical treatment course, post-operative management, and follow-up as
they pertain to the updated guidelines.
Conclusions: Despite recent updates in guidelines in the diagnosis and management of HDGC, the disease remains
challenging to address with patients given the high level of uncertainty and the comorbidities associated with
prophylactic intervention. We strongly recommend that an interdisciplinary team inclusive of clinical and surgical
oncologists, along with geneticists, social work, and psychological support, should follow the patients in a longitudinal
and comprehensive manner in order to achieve full recovery and return to normalcy, as with our patients.
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Background
Cancer is gaining ground over cardiovascular disease as
the leader of all-cause mortality, and gastric cancer is an
important contributor with approximately 720,000 an-
nual deaths [1, 2]. Although the majority of gastric can-
cers are sporadic in nature, approximately 1–3% of the
reported cases are related to inherited cancer predispos-
ition syndromes [3, 4], known as hereditary diffuse gas-
tric cancer (HDGC). Several genetic mutations have
been linked to HDGC, with heterozygous cadherin-1
(CDH1) germline mutations having the strongest clinical
association and being present in up to 40% of cases [4].
CDH1 codes for the tumor suppressor protein
E-cadherin and serves as an adhesion molecule at the
basement membrane of epithelial cells and mediates
downstream signaling cascades [5].
In families with CDH1 mutations, there is a cumula-
tive risk of 70 and 56% in males and females, respect-
ively, of developing HDGC by age 80 [4]. Additionally,
CDH1 mutations are highly associated with development
of lobular breast cancer (LBC), with a cumulative risk of
42% in females by age 80 [4]. These estimates demon-
strate the significance of the CDH1 germline mutations
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in developing HDGC and LBC, especially when consid-
ering that the lifetime risk of the general population in
developing these cancers is 0.9% in either gender for dif-
fuse gastric cancer (DGC) and 12% for breast cancer
(BC) in females [2].
These observations, combined with advances in gen-
etic diagnostics, endoscopic methods, and laparoscopic
surgery, led a multinational expert task force to update
clinical guidelines on how to approach HDGC in 2015
[3]. The case series presented here, from the Cancer
Treatment Centers of America in Zion, Illinois, de-
scribes the cases and management of three siblings with
a mother, sister, and grandparents who had passed away
from HDGC or LBC. Being one of the earliest case
reports since the updated guidelines, we placed special
emphasis in addressing several important points
addressed within those guidelines.
Case presentation
Case 1
Patient 1 is a 34-year-old Caucasian male with a past
medical history of gastroesophageal reflux disease
(GERD) and peptic ulcer disease (PUD) who presented
to the emergency department of an outside hospital with
sudden onset and worsening epigastric pain. A com-
puted tomography (CT) scan of the abdomen showed
mild ascites within the pelvic cavity and thickening of
the gastric antrum. Transabdominal ultrasound con-
firmed a small amount of ascites that did not require
paracentesis. Esophagogastroduodenoscopy (EGD) re-
vealed a chronic-looking, deep ulcer with radiating folds
at the antral region of the lesser curvature of the stom-
ach measuring 1.5 cm in diameter. Biopsy of the speci-
men revealed poorly differentiated, signet ring cell
carcinoma (SRCC) without Helicobacter pylori co-infection.
Positron emission tomography (PET) scan indicated active
disease in the stomach and no evidence of locoregional or
distant metastasis.
At this point, the patient presented at our institution
for a specialized, second opinion on the management of
his malignancy. Endoscopic ultrasound (EUS) and diag-
nostic laparoscopy with peritoneal washings did not
identify nodal involvement or intraperitoneal metastatic
disease, respectively, clinically staging the tumor as
cT2N0M0. Per NCCN guidelines, the patient underwent
three cycles of neoadjuvant chemotherapy with ECX
regimen (epirubicin 50 mg/m2, cisplatin 60 mg/m2, and
capecitabine/xeloda 625 mg/m2), which were tolerated
well by the patient. Re-staging CT scan of the abdomen
showed moderate regression of the cancer. Four weeks
after completion of the last dose of ETC, the patient
underwent total gastrectomy and omentectomy with
Roux-en-Y esophagojejunostomy and feeding jejunost-
omy tube (j-tube) placement.
Pathology of the tissue revealed invasive, poorly differ-
entiated gastric adenocarcinoma with singlet ring cell
features that invaded into the muscularis propria and
subserosal tissue, but with no evidence of invasion of the
visceral peritoneum (T3) (Fig. 1a, b). Presence of malig-
nant tissue was also confirmed with cytokeratin 7 immu-
nostaining (Fig. 1c). The size of the tumor was 2.2 × 2 ×
0.6 cm with negative margins, but with 3 of 41 lymph
nodes positive for metastatic adenocarcinoma as evi-
denced by cytokeratin AE1/AE3 immunostaining
(N2) (Fig. 2). With no identified distant metastases,
the pathologic staging of the tumor was ypT3N2M0,
stage IIIA.
The patient recovered post-operatively without com-
plications. Upon resumption of oral and j-tube feedings,
the patient was discharged from the hospital and
returned to work approximately 1 month later. Six
weeks post-surgery, the patient began adjuvant chemo-
therapy with TCX (epirubicin was substituted for taxo-
tere) for three cycles. Patient is currently under
surveillance, and the most recent CT scan of the chest,
abdomen, and pelvis identified no active signs of disease.
Up to the time of the preparation of this manuscript, the
patient continues to follow without clinic and currently
displays no evidence of disease.
During the early course of medical workup at our in-
stitution, the patient received genetic counseling based
on the high incidence of gastric and breast cancer in the
family. Specifically, his mother was diagnosed with gas-
tric cancer and died of the disease at the age of 49, while
his sister died of the same disease at the age of 25. Fur-
ther inquiry revealed that the maternal grandfather had
also succumbed to what was likely gastric cancer based
on the disease course provided by our patient, although
a definitive diagnosis was never made. Furthermore, two
maternal aunts were diagnosed with breast cancer in
their 50s and 60s. The strong prevalence of these two
cancers within the patient’s maternal lineage raised sus-
picion for possible hereditary diffuse gastric carcinoma
(HDGC) secondary to a genetic mutation in the CDH1
gene, particularly based on the recently updated guide-
lines [3]. Subsequent genetic analysis at our institution
confirmed a monoallelic deletion of exons 1–2 of the
CDH1 gene, further corroborating the clinical diagnosis.
Case 2
Patient 2 is a 32-year-old male and a younger sibling of
patient 1. Given the recently identified CDH1 mutation
and HDGC diagnosis in his sibling, patient 2 had a 50%
likelihood of being a CDH1 mutation carrier. Subse-
quent genetic screening at our institution confirmed that
similarly to his older sibling, patient 2 had a monoallelic
deletion of exons 1–2 of the CDH1 gene, predisposing
him to the HDGC like several members of his family.
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Initial CT scan of the chest, abdomen, and pelvis and
EGD biopsy of gastric tissue indicated no sign of active
malignancy. However, given the ~ 70% lifetime chance of
developing HDGC, the patient was recommended
prophylactic gastrectomy despite showing no signs or
symptoms of disease. The patient agreed with the rec-
ommendation and underwent prophylactic total gastrec-
tomy with Roux-en-Y esophagojejunostomy and feeding
j-tube placement. Immunohistochemical analysis of gas-
tric and intestinal tissue identified three microscopic foci
of signet ring cells in the lamina propria without inva-
sion of the submucosa (Fig. 3a, b), consistent with poorly
differentiated adenocarcinoma of the stomach. The rest
of the intestinal tract showed no signs of malignancy,
and 0 of 30 tested lymph showed positive for metastatic
carcinoma. The tumor was pathologically staged as
pT1aN0M0.
The patient recovered without complications and was
discharged home on post-operative day 7. He returned
to the emergency department 5 days later due to diffuse
abdominal pain, dark-colored emesis, and no bowel
movements for 2 days. Initial CT scan of abdomen and
pelvis revealed dilated, gas-filled, small bowel loops.
With the presumed diagnoses of ileus vs. partial small
bowel obstruction, the patient was re-admitted to the
surgical floor for further management. Subsequent tests
were unremarkable except for elevated amylase of
286 U/L and lipase of 1153 U/L, suggesting pancreatitis
as a more likely source for his abdominal pain. The
patient was managed per pancreatitis protocol and
recovered well. He was subsequently discharged from
our institution and continues to do well without evi-
dence of disease at the time of this manuscript.
Case 3
Patient 3 is a 23-year-old female and youngest sibling of
the two aforementioned patients. Her past medical
history was relevant for generalized anxiety disorder and
gastritis, while family history was relevant for an off-
spring with cleft lip, another condition associated with
A 
B 
C 
Fig. 1 Patient 1 tissue biopsy. a Low-power field of hematoxylin and eosin (H&E) staining of gastric mucosa showing disorganized infiltrative
sheets of cells invading the lamina propria. b Varying degrees of high-power fields demonstrating sheets of signet ring cells (arrows) infiltrating
the muscularis mucosa. c Immunohistochemistry (IHC) with cytokeratin 7 confirming tumor tissue infiltrating muscularis mucosa
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CDH1 mutations. Her genetic screening revealed pres-
ence of the same genetic mutation that afflicted her
older siblings, namely, monoallelic deletion of exons 1–2
of the CDH1 gene. Initial CT scan of the chest, abdo-
men, and pelvis and EGD biopsy were unremarkable.
Similarly to her older brother, she agreed to undergo
prophylactic total gastrectomy with Roux-en-Y esopha-
gojejunostomy and j-tube placement despite exhibiting
no active signs or symptoms of disease. Immunohisto-
chemical analysis of gastric and intestinal tissue revealed
multiple microscopic signet ring cell foci varying in size,
with the largest measuring 1 mm at its largest diameter
(Fig. 4a, b). The tumor was confined to the lamina
propria without evidence of invasion into the sub-
mucosa. All 23 tested lymph nodes tested negative for
metastatic disease, and no other organ revealed signs of
malignancy, staging the tumor as pT1aN0M0.
The patient recovered without major complications
and was discharged on post-operative day 7 after
abdominal pain and nutrition were adequately managed.
A 
B 
Fig. 3 Patient 2 gastric tissue biopsy. a High-power field of H&E staining of gastric mucosa with magnification on the right panel showing islet of
signet ring cells (arrows) invading the lamina propria. b Immunohistochemistry (IHC) with cytokeratin 7 confirming tumor tissue infiltrating the
lamina propria
1 
2 
2 
Fig. 2 Patient 1 lymph node infiltration. a H&E and b cytokeratin AE1/AE3 IHC staining of one of the three positive lymph nodes showing
disorganized epithelial tissues present and infiltrating the matrix of the lymph node
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Furthermore, the patient was offered prophylactic bilat-
eral mastectomy given the increased incidence of LBC in
women with CDH1 mutations. Initially, the patient re-
fused the procedure citing the desire to breastfeed her
future children and the low incidence of the disease
prior to the age of 30. However, she subsequently con-
sented to the procedure and underwent successful
prophylactic bilateral mastectomy. During her outpatient
recovery, patient 3 developed symptomatic gallstones.
She re-admitted for a third time to undergo elective
cholecystectomy and recovered without complications.
She continues to follow-up with our clinic and currently
displays no evidence of disease.
Discussion
Although gastric cancer (GC) is a leading cause of can-
cer mortality worldwide, hereditary diffuse gastric cancer
(HDGC) is relatively rare. As a consequence, best man-
agement options are based mostly on conclusions drawn
from small case series articles and retrospective analyses
and are therefore still not entirely agreed upon. In 2015,
a multidisciplinary workshop revised the criteria for
diagnosing HDGC mainly based on a recent large CDH1
sequencing study in patients with HDGC [3, 4]. Part of
the revisions involved updating the criteria for HDGC
diagnosis. New guidelines recommend establishing a
diagnosing of HDGC if the one or more of the following
are present: (i) two diagnoses of GC in a family, regard-
less of age, with at least one confirmed as diffuse GC;
(ii) one diagnosis of DGC in someone younger than 40;
or (iii) personal or family history of DGC and LBC, with
at least one before the age of 50 [3]. In this report, we
presented a case series of three siblings who fulfilled all
three HDGC diagnostic criteria, making this one of the
earliest clinical reports since the new guidelines were
implemented. We closely followed the new guidelines
and address below some of the salient issues that arose
during the management of these patients.
Hansford et al. undertook the ambitious effort of gen-
etically sequencing the blood of 183 patients with the
clinical diagnosis of HDGC [4]. To date, that is the lar-
gest study investigating CDH1 mutations in the context
of HDGC and provides invaluable yet difficult data to
discuss with patients. Specifically, they found that men
harboring germline CDH1 mutations have a 70% chance
of developing HDGC by the age of 80, while women
have a 56% of developing the same.
While to many patients the risks inherent in these
numbers are unacceptable and immediate prophylactic
gastrectomy is an obvious decision regardless of age, for
others, whether and when to have such a life-altering
procedure can be a particularly sensitive topic. This
decision is made difficult by several conflicting factors.
On the one hand, prophylactic gastrectomy is curative
(i.e., it reduces the risk of developing HDGC to virtually
0%); this contrasts drastically with the fact that patients
who develop diffuse GC have a dismal 5-year overall sur-
vival rate of 10–20% [6]. On the other hand, prophylac-
tic gastrectomy itself comes with numerous life-altering
implications and risks such as infections, dumping syn-
drome, and a post-operative mortality rate of approxi-
mately 1% [7, 8]. Indeed, two of the patients’ relatives
who had tested positive for CDH1 at a later date and
were treated at outside institutions suffered major
A 
B 
Fig. 4 Patient 3 gastric tissue biopsy. a High-power field of H&E staining of gastric mucosa with magnification on the right panel showing islet of
signet ring cells (arrows) invading the lamina propria. b Immunohistochemistry (IHC) with cytokeratin 7 confirming tumor tissue infiltrating the
lamina propria
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complications post-operatively, with an aunt suffering an
anastomotic stricture post-gastrectomy, while another
dying from pulmonary embolism complications. Add-
itionally, these patients are also afflicted with long-term
alteration of their ability to digest and absorb nutrients,
often resulting in drastic weight loss and permanent GI
disturbance [9, 10]. This can have both physical as well
as psychosocial implications for afflicted patients.
These conflicting interests became evident in our case
series. Patients 2 and 3 were willing to undergo immedi-
ate prophylactic gastrectomy upon positive genetic test-
ing as they believed the risk of developing diffuse GC far
outweighed the risks and side effects of total gastrec-
tomy. A fourth sibling, who was not included in the
study, refused gastrectomy at this time because he be-
lieved the opposite: the risk of developing GC at this
time was not as consequential for him as the outcome of
total gastrectomy. Deciding the ideal time to undergo
prophylactic gastrectomy can be very challenging even
with statistical models in hand. Even within this family,
the time of onset of GC varied dramatically, with patient
1 at 34, the mother at 49, and another sister at 25. It is
important to emphasize that patients who forego
prophylactic gastrectomy should undergo annual screen-
ing with EGD and biopsies [3, 4]. However, as evidenced
by the fact that screening EGD biopsies failed to identify
the carcinoma in situ in both cases 2 and 3, annual EGD
should not be offered as an equivalent alternative to
prophylactic gastrectomy, but rather it should be re-
served only for patients who refuse or delay prophylactic
treatment.
It is also important to note that patient 2 suffered sig-
nificant emotional and physical distress before, during,
and after the procedure. In addition to the brief compli-
cation of pancreatitis after surgery, he continuously
expressed anxiety regarding his muscle weight loss and
difficulty with oral food intake. To help him through the
process, we followed the updated guidelines, planned
and executed numerous scheduled phone calls with our
nutritionist, psychologist, and genetic counselor to help
him through the early post-operative stages, when most
of these symptoms were prevalent. After months of close
follow-up, the patient has fully recovered on a nutri-
tional perspective and resumed arm-wrestling, his per-
sonal hobby.
Although patient 3 underwent prophylactic gastrec-
tomy, she initially decided not to undergo prophylactic
bilateral mastectomy, which would drastically reduce her
risk of developing LBC in the future. Citing her desire to
breastfeed her current and potential future children, she
decided to proceed with annual screening mammog-
raphy and MRI starting at the age of 30, as per the new
guidelines [3, 4]. However, upon further counseling with
family members, our geneticist, social worker, and other
healthcare professionals, she reversed her original deci-
sion and decided to proceed with prophylactic mastec-
tomy instead. This case further demonstrates that
determining when a patient should undergo a prophylac-
tic procedure should be individualized and based on pa-
tients’ goals, especially for women of childbearing age.
Even when tailored to a specific patient, the treatment
plan should be fluid, and the healthcare team should be
ready to accommodate patients’ changing preferences.
Since over 92% of prophylactic gastrectomies in CDH1
mutated patients with family history of HDGC will re-
veal SRCC on pathologic examination, a recent study
suggested presenting the total gastrectomy procedure to
patients as a curative, rather than a prophylactic option
[11, 12]. This, as hypothesized, would increase patients’
inclination to undergo the procedure, as patients are in-
clined to get curative rather than preventative treat-
ments. Consisted with these data, both our
asymptomatic patients (patients 2 and 3) showed evi-
dence of SRCC despite having no evidence of disease on
imaging and endoscopic sampling. It could be possible
that the fourth sibling may have decided to undergo
total gastrectomy if the procedure was offered as a cura-
tive, rather than as a prophylactic procedure, and that
his histologic findings would possibly reveal SRCC.
However, we believe that such semantics should not play
a major role in a patient’s decision to undergo such an
important surgical procedure. Rather, the authors believe
that regardless of the terminology used, the patient
should be offered all the facts at our disposal about the
risks and benefits of undergoing a certain procedure and
allow the patient to make the decision that best suits
one’s life philosophy and goals.
Although our article centers on a case series with
HDGC secondary to a germline CDH1 mutation, it is
important to note that a diagnosis of HDGC is made
based on clinical and family history and is not ruled out
by a negative CDH1 genetic testing results. In fact, the
Hansford et al. study found that only 34 out of 183, or
not even 20% of patients with clinical diagnosis of
HDGC, harbored CDH1 mutations [4]. While this num-
ber is lower than the 40% that is historically reported
[13–16], it does underscore the fact that absence of a
readily identifiable mutation in patients with strong clin-
ical and family history suspicious for HDGC does not
rule out the presence of the condition and that further
testing, such as sequencing other genes, can and should
be pursued. The same study by Hansford et al. identified
CTNNA1, a gene that codes for α-catenin, as another
culprit in HDGC, and that should be screened in pa-
tients where clinical suspicion is high but CDH1 genetic
testing is unremarkable [4].
Conversely, while the presence of a germline CDH1
mutation strongly increases the clinical suspicion of
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HDGC, particularly in patients with family history of
gastric or lobular cancer, not all CDH1 mutations are
pathogenic or cause HDGC. A study from France se-
quenced 165 individuals at random and identified 18
germline CDH1 mutations [17]. Of these, only 11 ful-
filled the new criteria of HDGC, suggesting that a mere
germline CDH1 mutation is not sufficient to attribute a
diagnosis of HDGC in a family.
Conclusions
Gastric cancer continues to be a leading cause of
cancer-related mortality worldwide, and HDGC con-
tinues to be measurable and potentially a preventable
contributor to these deaths. To our knowledge, here we
presented one of the earliest case series on CDH1-me-
diated HDGC since the implementation of the new
HDGC guidelines. We noted that updated diagnostic
guidelines appear to adequately diagnose the disease, as
our patients’ family fulfilled all three criteria at once.
Interestingly, despite recent knowledge about the disease
and clinical recommendations, the best course of action
in each case continues to remain a sensitive subject and
should be individualized for each patient. We noted that
a strong multidisciplinary support group including ge-
neticists, clinical and surgical oncologists, nutritionist,
psychologist, and social workers is key in successfully
carrying these patients through this challenging journey.
Lastly, although presence of CDH1 mutation in a family
with clear history of DGC and LBC, it is important to
remember that additional mutations can also cause
HDGC.
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